Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Type I and III procollagen propeptides in growth hormone-deficient patients: effects of increasing doses of GH.

Research output: Contribution to journalJournal articleResearch

  1. Urinary growth hormone excretion in acromegaly: diagnostic value in mild disease activity

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Impaired pancreatic polypeptide response to a meal in type 1 diabetic patients: vagal neuropathy or islet cell dysfunction?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Bone metabolism in obesity: changes related to severe overweight and dietary weight reduction.

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Effects of thyrotropin-releasing hormone on regional cerebral blood flow in man

    Research output: Contribution to journalJournal articleResearchpeer-review

  • L T Jensen
  • J O Jørgensen
  • J Risteli
  • J S Christiansen
  • I Lorenzen
View graph of relations
The effect of increasing doses of growth hormone on collagen synthesis in GH-treated GH-deficient patients was determined in a short-term study. The synthesis of type I and III collagen was estimated by measurements of the carboxyterminal propeptide of type I procollagen and the aminoterminal propeptide of type III procollagen. Type I collagen is mainly found in bone and type III collagen in loose connective tissue. We observed a GH dose dependency of both procollagen propeptides. Serum type I procollagen propeptide was significantly higher following GH doses of 4 and 6 IU/day for 14 days compared with 2 IU/day (normal replacement dose) (p = 0.04). Withdrawal of GH therapy for 14 days resulted in wider variation, but not significantly different from the levels at 2, 4 and 6 IU/day. A dose dependency was found regarding type III procollagen propeptide, showing significantly higher serum concentrations at a GH dose of 4 IU/day compared with 2 IU/day (p = 0.001), and of 6 IU/day compared with 4 IU/day (p = 0.001). Withdrawal of GH therapy resulted in significantly lower type III procollagen propeptide concentrations compared with those at a GH dose of 4 and 6 IU/day (p = 0.03). Serum type III procollagen propeptide increased twice as much as type I procollagen propeptide, by 47 vs 25%, at a GH dose of 6 IU/day compared with 2 IU/day. The differences between the effects on type I and type III collagen may reflect differences in secretion or turn-over rate of collagen in bone and loose connective tissue.(ABSTRACT TRUNCATED AT 250 WORDS)
Translated title of the contributionType I and III procollagen propeptides in growth hormone-deficient patients: effects of increasing doses of GH.
Original languageEnglish
JournalActa Endocrinologica (Copenh)
Volume124
Issue number3
Pages (from-to)278-282
Number of pages5
ISSN0001-5598
Publication statusPublished - 1991

ID: 32552892